Epilepsy and Developmental Delay in Pediatric Patients With PTEN Variants and a Literature Review

Qinrui Li1, Zhao Xu1, Jiong Qin1

  • 1Department of Pediatrics, Peking University People's Hospital, Beijing, China; Epilepsy Center, Peking University People's Hospital, Beijing, China.

Pediatric Neurology
|December 7, 2024
PubMed

Insights

Pediatric patients with phosphatase and tensin homolog (PTEN) variants often experience developmental delays. Epilepsy in these children, primarily focal seizures, generally responds well to medication, especially with normal brain imaging.

Area of Science:

  • Pediatric Neurology
  • Genetics
  • Epilepsy Research

Background:

  • Epilepsy is uncommon in pediatric patients with phosphatase and tensin homolog (PTEN) variants.
  • Characteristics of epilepsy, medication response, and prognosis in these patients are not fully understood.

Purpose of the Study:

  • To elucidate the characteristics of epilepsy in pediatric patients with PTEN variants.
  • To understand the developmental outcomes in pediatric patients with PTEN variants.

Main Methods:

  • Data collected from pediatric patients at Peking University People's Hospital (July 2018–April 2024).
  • Review of published literature on PTEN variants and epilepsy.

Main Results:

  • 13 pediatric patients with PTEN variants identified; 15.4% had epilepsy, responding well to antiseizure medications.
  • Focal seizures were the most common type (66.7%) among 26 epileptic patients from literature review.
  • Drug-resistant epilepsy was noted in 28.6% of patients with available data.

Conclusions:

  • Pediatric patients with PTEN variants have a high rate of developmental delay.
  • Focal epilepsy is common in this cohort, with good medication response often linked to normal brain imaging.
  • Further large-scale studies are needed to characterize epilepsy in pediatric PTEN variant patients and standardize treatments.
Abstract

Related Concept Videos

Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
177
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
300
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
127
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
328